Mitogen-Activated Protein KinaseKinase 3 (MAP2K3) is a member of the dual specificity kinase group. Growing evidence links MAP2K3 to invasion and tumor progression. Here, we identify MAP2K3 as a transcriptional target of endogenous gain-offunction p53 mutants R273H, R175H, and R280K. We show that MAP2K3 modulation occurred at the mRNA and protein levels and that endogenous mutp53 proteins are capable of binding to and activate the MAP2K3 promoter. In addition, we found that the p53 mutants studied regulate MAP2K3 gene expression through the involvement of the transcriptional co-factors NF-Y and NFkB. Finally, functional studies showed that endogenous MAP2K3 knockdown inhibits proliferation and survival of human tumor cells, whereas the ectopic expression of MAP2K3 can rescue the proliferative defect induced by mutp53 knockdown. Taken together, our findings define a novel player through which mutp53 exerts its gain-offunction activity in cancer cells.
TP53 gene mutations are the most frequent genetic alterations in human cancers; more than 50% of all human cancer cases carry mutations within the TP53 locus (1) . Most of them are missense point mutations and are localized in the core DNA-binding domain (2) . These alterations disrupt the normal transcriptional capacity of p53 and compromise its tumor suppressor properties by abrogating its transcriptional activity on genes connected with cell cycle arrest, apoptosis, or DNA repair, in response to a variety of stress signals (3, 4) . Recent studies have shown that mutations of the TP53 gene can confer additional functions (gain-of-function, GOF) that are exerted in a variety of ways, ranging from enhanced proliferation in culture, increased tumorigenicity in vivo, and enhanced resistance to a variety of commonly used anticancer drugs (5, 6) . The GOF hypothesis has recently been reinforced by studies employing mutp53 (mutp53) "knock-in" mice, which show a higher frequency of tumor development and increased metastatic potential, compared to p53-deficient mice (7, 8) . Furthermore, RNA interference (RNAi) studies demonstrated that depletion of mutp53 renders cancer cells more sensitive to DNA damaging chemotherapeutic agents in vitro (9, 10) and reduces tumor malignancy both in in vitro and in vivo (10) . In agreement with these results, tumor growth delay studies, performed in the HT29 xenograft model, showed that conditional silencing of mutp53 does not only impact on tumor growth but leads to tumor architecture modifications, with consistent reduction in stromal invasion and tumor angiogenesis (11) . At the molecular level, these GOF effects were shown to be linked to the ability of mutp53 to modulate the expression of several genes, such as MDR1 (12) , c-myc (13) , CD95 (Fas/APO-1) (14) , EGR1 (9) , MSP/MST-1 (15) , GEF-H1 (16), Id2 (17) , GRO1 (18) , PPARGC1A, FRMD5 (19) , and Id4 (20) , supporting the hypothesis that mutp53-specific transcriptional activity is required for at least some of the mutp53 GOF effects. However, the molecular mechanisms underlying the GOF of mutp53 proteins are still far from being understood. Two different and not mutually exclusive possibilities are currently considered: (i) mutp53 retains residual transcriptional activity, and acts as regulator of transcription (19, (21) (22) (23) (24) ; (ii) mutp53 can no longer bind DNA but interacts with other transcription factors and modulates their activities (25) (26) (27) .
The mitogen-activated protein kinasekinase 3 (MAP2K3) belongs to a dual specificity kinase group (MKK-) and is activated by MKKK proteins (MEKK1-4) through Ser-189 and Thr-193 phosphorylation (28) . MAP2K3 is a specific upstream activator of the p38MAPK protein (28) . Recent studies found MAP2K3 upregulation involved in invasion and progression of gliomas and breast tumors (29) . Our recent qPCR validation of microarray data, from cells expressing endogenous mutp53 (HT29 and SKBR3) and xenograft tumors, indicated that MAP2K3 (also known as MKK3) is a mutp53 target gene (11) . To unveil a possible role of MAP2K3 upregulation in mutp53 GOF activity, we studied in different cell lines the molecular mechanisms through which different mutp53 proteins upregulate MAP2K3 expression and the biologic effects of its upregulation.
Here, we find that different mutp53 proteins bind the MAP2K3 promoter, enhancing its trascriptional activity. Moreover, by dissecting the MAP2K3 promoter region, we identify co-activators required by mutp53 to upregulate MAP2K3 expression. Finally, biological studies indicate that MAP2K3 upregulation plays an important role in cell proliferation and survival. Overall, our study defines MAP2K3 as a novel target of mutp53 and provides new insights for the understanding of mutp53 GOF activity.
EXPERIMENTAL PROCEDURES
Cell lines-Non-small cell lung carcinoma H1299 (p53-null), colon adenocarcinoma HT29 (mutp53R273H), breast carcinoma SKBR3 (mutp53R175H) (10), breast adenocarcinoma MDA-MB468 (mutp53R273H) (provided by Dr. G. Blandino), and colorectal carcinoma HCT116 (wtp53) (provided by Dr M. Fanciulli) human cell lines were maintained in DMEM (Eurobio, Les Ulis, France). Human breast carcinoma cell line MDA-MB231 (mutp53R280K) (provided from Prof. S. Andò) was maintained in DMEM-F12 1:1. All mediums cell cultures were supplemented with 10 % FBS (GIBCO-BRL, Grand Island, NY), 2 mM L-glutamine (Life Technologies Inc., Eggenstein, Germany), 100 U/ml Penicillin/100 µg/ml Streptomycin (Life Technologies Inc.). HEK293T packaging cell line (11) were maintained in DMEM high glucose (GIBCO-BRL) 10 % FBS, 2 mM Lglutamine, 100U/ml Penicillin 100 µg/ml Streptomycin, 1X non-essential aminoacids (GIBCO-BRL). All cell lines were maintained at 37°C in a humidified environment of 5 % CO2. Western blotting-Cells were washed twice in ice-cold PBS, harvested by scraping into 1X RIPA buffer (150 mM NaCl, 1 % TritonX100, 0.25 % Sodium deoxycholate, 0.1 % SDS, 50 mM Tris/HCl ph 8.0, 20 mM EDTA) supplemented with 1X protease and phosphatase inhibitor cocktail (Sigma-Aldrich), 1mM PMSF (Sigma-Aldrich, Germany), 50 mM Sodium Fluoride (Sigma-Chemical Co. MO, USA), and 50 mM Ditiotreitol (Bio-Rad Laboratories Inc). Lysates were incubated 30 min in ice, clarified by centrifugation, and resolved onto 10 % SDS-PAGE (30 µg/lane). Blotting was performed according to standard protocols and filters were immuno-reacted with following antibodies: p53 mouse monoclonal antibody (DOI) (6), MAP2K3 rabbit polyclonal antibody (Cell Signaling #9232), phospho-ATF2 rabbit polyclonal antibody (Upstate, clone AW65), Flag mouse monoclonal antibody (Sigma, M1), NF-kB goat polyclonal antibody (p50, SantaCruz, C-19 SC-1190), and actin mouse monoclonal antibody (Ab-1, Calbiochem, San Diego, CA). Secondary HRP-conjugated antibodies anti-mouse (Santa Cruz Biotechnology, CA) or anti-rabbit (Calbiochem respectively) were used. Detection of immunoreactions was performed by ECL kit (Amersham Biosciences, Little Chalfont, UK). Densitometric analyses were performed by Scion-image software. MAP2K3 Promoter Constructs-A fragment of 1.0-kb of the MAP2K3 gene 5'-regulatory region (-989 to -2 respect to the translational start site) was PCR-amplified from HT29 genomic DNA by using information obtained from NCBI database. Primers were designed as follow: -Forward primer, includes a Sac1 restriction enzymes sequence plus a short tale (MAP2K3-For:
5'-tatagactat-GAGCTCACCACCGACCC-3'); -Reverse primers, includes a BglII restriction enzymes sequence plus a short tale (MAP2K3-Rev: 5'tataagatct-TGCAAGTGGGTCCTGGAC-3') (italic reports the restriction enzyme sites). PCR reaction was performed with HOT-MASTER Taq (Eppendorf). Amplified fragment was digested with SacI/BglII restriction enzymes (Invitrogen) and cloned into digested pGL3-Luc promoter-less vector generating pMAP2K3-luc. The new vector was then sequence analyzed. Deletion derivatives of MAP2K3 cloned promoter were generated as follow: -pdel1-Luc (deletion -989 to -716) was generated by cutting cloned promoter (pMAP2K3-Luc) with SacI restriction enzyme, T4 DNA polimerase blunt ended (Biolabs), PvuII digested (Invitrogen) and self-ligated (Takara DNA ligation Kit); -pdel2-Luc (deletion -782 to -499) was generated by cutting with SmaI (Invitrogen) dual restriction enzyme sites and self-ligated; -pdel3-Luc (deletion -711 to -167) was generated by cutting with PstI restriction enzyme (Boehringer Mannheim, Germany) and self-ligated. Transactivation assay-Cells were plated in 6-well plates (5x10 4 cells/well), and the day after cells were transiently transfected with vector reporter (0.9 µg/well) and pCMVb-GAL (0.1 µg/well) (transfection efficiency) vector by following lipofectamin/plus guidelines (Invitrogen). Luciferase and b-galactosidase assays were performed 24 hrs later on whole-cell extract, as described (30) . Luciferase values were normalized to b-galactosidase activity and protein contents. H1299 cells were plated in 6-wells plate (5x104cells/well), and 24 hrs later cells were transiently co-transfected with either the pMAP2K3-Luc o the partial deleted promoters (0.8 µg/well) along with the pCMVb-GAL (0.1 µg/well) and either p53 expressing (0.1 µg/well) vectors. Luciferase and bgalactosidase assays were sperformed 24 hrs later as reported. Chromatin Immunoprecipitations (ChIP)-ChIP assays were performed as previously described (31) . In brief, cells were incubated in 1% of formaldehyde for 10 minutes at 22°C. The reaction was stopped by addition of glycine to 125 mM final concentration. Sonicated chromatins were incubated with following antibodies: anti-p53 (6 µl/reaction) (ab-7, Oncogene n°PC35); anti-NF-YB (3 µg/reaction) (generous gift from Dr. R. Mantovani); anti-NFkB (10 µl/reaction) (p50) (Santa-Cruz, C-19 SC-1190), anti-PAN-H4ac (10 µg/reaction) (Upstate, n°06-598). For PCR analyses 2 µl of template in 20-30 µl of total reaction were used. PCR was performed with HOT-MASTER Taq (Eppendorf) by using following primers:
Primer sequences of adjacent region to hMAP2K3 promoter as negative control (-3200bp) were: -3200-For 5'-TTCTCAGTGCCAGTCACACAGTAA-3' and -3200-Rev 5'-GGCAGCTCCTTCATTCATTCA-3'. Viral vectors-Lentiviral vectors were produced in HEK293T cells, by transient trasfection as previously described (11) . Lentiviruses were harvested 48h later, centrifuged 5 min at 3,000 RPM, aliquoted and stored at -80°C. Lentiviral stocks were titered following standard protocols (32). Routinely, a viral titer of 106 transducing units per ml (TU/ml) was achieved. Design and cloning of shRNA-The shRNA sequence specific to hMAP2K3 (lab_hairpin_id 1:v2HS_170539) was identified by RNAi codex portal/database (33) . Selected sequence was then adapted for cloning in pLV-THM lentiviral vector.
Designed oligos 5'-cgcgtccGACATTGCTGCCTTCGTGAttcaagaga TCACGAAGGCAGCAATGTCtttttggaaat-3' and 5'-cgatttccaaaaaGACATTGCTGCCTTCGTGAtctc ttgaaTCACGAAGGCAGCAATGTCa-3' were annealed and cloned in pLV-THM vector MluI/ClaI (Boehringer Mannheim, Germany) digested. The new generated vector pLVTHsh/MAP2K3 was produced and titered, as reported. Cellular transduction-For constitutive RNA interference, cells were seeded in 24-well plate (3x10 4 cells/well), 24h later recombinant lentiviruses supplemented with 8.0 µg/ml of polybrene reagent (Sigma-Aldrich, #H-9268) were added to the cells. After 16h, cells were washed and replenished with fresh medium and, 96h later, processed for western blot analysis and/or proliferation assays. For conditional RNA interference, HT29 cells were plated in 24-well plate (3x10 4 cells/well). After 24h, medium containing LV-THsh/MAP2K3 and LV-tTR-KRAB lentiviruses supplemented with 8.0 µg/ml of polybrene was added to the cells. Following 16h of incubation, cells were washed and replenished with fresh medium. To monitor shRNA expression upon doxycycline Hydrochloride treatment (+Dox) (D9891, Sigma-Aldrich), new generated cell lines were plated and after 24h Dox (1.0 µg/ml) was added to the medium. Dox was replenished every three days. Then, 5 days later, cells were analyzed by Western blot. For stable ectopic expression of MAP2K3 cells were transfected with either vector: pCDNA3 (empty) or pRc/RSV-Flag-MAP2K3 (Addgene) following lipofectamine/plus guidelines (Invitrogen). Cells were selected by Geneticin (G418 sulfate, Invitrogen) and stable transfected cells analyzed by Western blot to monitor ectopic MAP2K3 expression. Flow cytometry analysis-Infected HT29 cells were maintained in either -/+Dox conditions (1.0 µg/ml). At different time points, cells were harvested, washed once in PBS/NaN3 1x, and fixed in MetOH:Acetic acid solution (4:1) for 60 minutes at +4°C. Then, cells were centrifuged, re-suspended in PBS/NaN3 1x supplemented with RNAase 2 µg/ml (150U/ml) and incubated, during the last 30 min, in the dark with 0.1µg/ml of Propidium Iodide (PI). Subsequently cells were analyzed by flow cytometry. Quantitative PCR-Q-PCR was performed using SYBR Green (Applied Biosystems) as marker for DNA amplification, on an ABI Prism 7500 apparatus (Applied Biosystems), with 50 cycles of two-step amplification. Samples were quantified in triplicate from 2 independent immunoprecipitations. The relative proportions of immunoprecipitated promoter fragments were determined based on the comparative threshold (DCt) method (31) . Primers sequences of the hMAP2K3 promoter used in the Q-PCR reactions were: Forward 5'-TTAACCCCCGCCCACTTC-3' and Reverse 5'-TGCGTCGTCTGGAAAAAACC-3' Statistical analysis-All experiments were performed in triplicate. Numerical data were reported as means + standard deviations (SD). Significances were assessed by Student's t-test analysis.
RESULTS

Mutp53
upregulates MAP2K3 protein expression. We previously showed (11) that exogenous expression of mutp53R175H, in p53-null H1299 cells, significantly increases MAP2K3 mRNA. Conversely depletion of endogenous mutp53R175H or mutp53R273H proteins by RNAi induced a sizeable reduction of MAP2K3 mRNA levels in human cancer cell lines (11) . We wished to verify whether the observed upregulation of MAP2K3 gene expression by mutp53 translates into increased MAP2K3 protein levels. To this aim, we first explored its modulation in p53-null H1299 cells upon ectopic expression of the wild-type (wt) p53, mutp53R175H or mutp53R273H proteins. As shown in Fig. 1A , ectopic expression of the p53 mutants induced a significant increase in MAP2K3 proteins levels, compared with emptyvector (pcDNA3) transfection. On the contrary, no significant effects were observed upon ectopic expression of wt p53 (Fig. 1A) . To confirm these results in a more relevant cellular context, similar experiments were performed with a panel of human cancer cell lines naturally harboring mutations in the TP53 locus. MAP2K3 modulation was assessed upon RNAi depletion of endogenous mutp53 in SKBR3 (mutp53R175H), MDA-MB468 (mutpR273H),
MDA-MB231
(mutpR280K) and HT29 (mutpR273H) cell lines. The cells were transduced with either lentiviral vectors carrying short hairpin RNAs (shRNAs) specific to p53 (sh/p53) or control scrambled shRNA (sh/scr) (11) . mutp53 depletion induced a significant reduction in MAP2K3 protein levels in all tested cell lines (Fig.1B, lanes 2, 4, 6, 8) . In contrast, similar experiments performed with wt 53-expressing cells (HCT116) showed no modulation of MAP2K3 protein levels (Fig.1B,  lane 10) . Overall, these data indicate that, in our cancer cell line panel, MAP2K3 is likely to be a common target of mutp53R273H, mutp53R175H and mutp53R280K proteins.
p53 mutants transactivate the MAP2K3 promoter. To determine whether mutp53 upregulates MAP2K3 expression through transactivation of its promoter, we cloned the MAP2K3 gene 5' regulatory region (-989 to -2) upstream of a luciferase gene, generating the pMAP2K3-Luc vector (see Experimental Procedures). The effect of mutp53 on MAP2K3 promoter activity was evaluated by transienttransfection assays in our cohort of human cancer cells. Cells infected with either the sh/p53-or the sh/scr-bearing lentiviral vector were transiently transfected 96 hrs later with either the pBasic-Luc (promoterless) or the pMAP2K3-Luc vector. Promoter activity was evaluated after further 24 hrs by luciferase assay. Fig. 2A shows that mutp53 actively contributes to MAP2K3 gene expression, though to different extents, in all tested cell lines. Consistently, depletion of endogenous mutp53 induces a significant reduction in luciferase activity. Similar experiments were then performed with p53-null H1299 cells, in which MAP2K3 promoter activity was assessed upon transient expression of either wt or mutp53 proteins (R175H, R273H). The results showed that the baseline MAP2K3 promoter activity, present in control cells, was not affected by wt p53 protein, whereas the ectopic expression of the R175H or R273H mutant induced significant increases in MAP2K3 promoter activity (Fig. 2B) . These data indicate that the analyzed cancer-associated p53-mutants can upregulate MAP2K3 expression via transactivation of the MAP2K3 promoter.
Mutp53 proteins are recruited onto the MAP2K3
promoter and modulate its activity through the -499 to -167 regulatory region. To identify the promoter region required for mutp53 to upregulate MAP2K3 gene expression, we generated three partial deletions in the cloned promoter, namely: -pdel1-Luc (-989 to -716 deletion), -pdel2-Luc (-782 to -499 deletion) and -pdel3-Luc (-711 to -167 deletion) (Fig.3A and see Experimental Procedures). To assess transcriptional activity, we initially performed experiments with HT29 cells harboring the p53R273H mutation. Cells were transiently transfected with the partially deleted, the fulllength (pMAP2K3-luc), or the promoterless (pBasic-Luc) reporter vectors and transcriptional activities were measured 24 hrs later. The pMAP2K3-Luc vector showed an activity about 10-fold greater than the promoterless construct. Similar activities were displayed by the pdel1-Luc and pdel2-Luc constructs. However, the -711 to -167 deletion completely abrogated promoter activity (pdel3-Luc, Fig.3B) . Confirmatory experiments were then performed with p53-null H1299 cells where the transcriptional activity of mutp53 proteins on the MAP2K3 promoter was explored by exogenously expressing different p53 mutants. The Luc-reporter vectors already described were co-transfected along with either the mutp53R175H-or the mutp53R273H-expressing vector and transcriptional activity was evaluated 24 hrs later. The full-length MAP2K3 promoter activity increased significantly upon expression of either p53 mutant protein (Fig.3C ). These two mutants showed similar activities on the pdel1-Luc and pdel2-Luc reporter constructs, while the pdel3-Luc construct showed transcriptional activity independent of the presence of p53 mutant proteins (Fig.3C ). In conclusion, our results show that the response to mutp53 proteins maps to the -499 to -167 promoter region.
Next, we asked whether mutp53 proteins contribute directly to MAP2K3 upregulation via physical recruitment onto the MAP2K3 promoter.
To this end, chromatin immunoprecipitation (ChIP) assays were performed on chromatin isolated from our human cancer cell lines infected with either the sh/p53 or the sh/scr lentivirus. Cyclin B2 was included in our experiments as a positive control, since it has been reported that the p53R175H mutant protein is recruited onto cell cycle-related gene promoters (25) . All endogenous mutants investigated (R273H, R175H, and R280K) were found to be recruited onto the MAP2K3 promoter in all tested cell lines (Fig.3D, lanes 1, 3, 5, 7) . The specificity of these results was confirmed by the absence of specific amplifications from mutp53-depleted cells. Furthermore, no amplification of an adjacent region (-3200bp) on the MAP2K3 promoter was detected. These findings indicate that upregulation of MAP2K3 occurs through in vivo recruitment of mutp53 proteins onto specific MAP2K3 regulatory regions.
Mutp53 regulates MAP2K3 gene expression through the NF-Y and NF-kB transcriptional co-
To identify transcriptional co-factors through which mutp53 might regulate MAP2K3 expression, we searched for consensus binding sites using the MatInspector software tool (http://www.genomatix.de/). An analysis of the mutp53-responsive promoter region (-499 to -167) showed that it includes consensus sequences for several transcription factors, but no TATA box. Therefore, among the transcription factors potentially binding this region, we focused on those known to functionally interact or form complexes with mutp53, such as NF-Y (25) and NF-kB (20, 26, 27) (Fig.4A) . To ascertain their involvement in mutp53-mediated MAP2K3 upregulation, we first analyzed the in vivo recruitment of NF-Y and NF-kB on MAP2K3 regulatory regions. ChIP analyses were performed on chromatin from HT29 cells transduced with either the sh/p53 or sh/scr lentivirus. Chromatin was immunoprecipitated with antibodies to NF-YB, NF-kB (p50), or acetylated histone H4 (H4ac). The last one was chosen to assess the accessibility of the chromatin regions analyzed. The results showed that both transcriptional cofactors are recruited to the MAP2K3 regulatory region. In particular, NF-Y occupancy did not vary between the analyzed conditions (sh/p53 and sh/scr cells) (Fig. 4B, left panel, lane 1) , in agreeement with published data (24) . In contrast, a reduced recruitment of NF-kB (p50) was observed in sh/p53, compared with sh/scr cells (Fig.4B left panel, lane 3) . Acetylated histone 4 behaved similarly to NF-kB (Fig. 4B left panel,  lane 2) , further confirming that the MAP2K3 promoter activity was significantly reduced by mutp53 depletion. qPCR measurements confirmed quantitatively the observed effect (Fig. 4B, right panel) . The absence of signal in an adjacent region (-3200 bp) demonstrated the specificity of the results. To rule out the possibility that mutp53 affects the steady state levels of NK-kB, thereby altering MAP2K3 expression, we monitored NF-kB protein in H1299 cells upon exogenous expression of either the mutp53R175H or mutp53R273H protein. Supp. Fig 1 shows that ectopic expression of the mutants does not modify NFkB protein levels with respect to control cells.
To evaluate the functional involvement of NF-Y and NF-kB in mutp53-mediated MAP2K3 upregulation, we exploited dominant-negative mutants of NF-Y (YA13m29) (34) or NF-kB (IkBa super-repressor, IkBa-SR) (35) . p53-null H1299 cells were transiently co-transfectd with the full-length promoter (pMAP2K3-luc) along with the mutp53R175H, or mutp53R273H, or empty (pcDNA3) vector, and increasing amounts of either YA13m29-or IkB-SRexpressing vector. Transcriptional activity was measured 24 hrs later. These experiments showed that the increased MAP2K3 promoter activity induced by p53 mutants was significantly repressed in the presence of either dominant-negative mutant (Fig.4C) . Taken together, our findings indicate that mutp53 upregulates MAP2K3 expression through the involvement of NF-Y and NF-kB transcriptional co-factors.
Knockdown of endogenous MAP2K3 protein interferes with mutp53 GOF effects.
To evaluate whether MAP2K3 contributes to mutp53 GOF activity, we explored the biologic effects of depleting the endogenous MAP2K3 protein by RNAi. To this end, we constructed a lentiviral vector bearing a MAP2K3 shRNA (see Experimental Procedures). HT29 cells conditionally expressing the MAP2K3 or the sh/scr shRNA were generated as previously described (11) . The engineered cell lines were then challenged with doxycycline (+Dox) and MAP2K3 depletion efficiency was monitored. Maximal depletion of endogenous MAP2K3 was achieved after 144 hrs of +Dox treatment (Fig.  5A, left-panel) . In addition, since MAP2K3 is a specific upstream activator of p38MAPK (28), we evaluated whether silencing MAP2K3 compromises its signaling cascade by monitoring the phosphorylation status of ATF2, a downstream factor of p38MAPK. Indeed, depletion of MAP2K3 causes a significant reduction in phospho-ATF2 at 144 hrs of +Dox treatment (Fig. 5A, left-panel) . Accordingly, depletion of the endogenous mutp53R273H protein sharply reduced ATF2 phosphorylation ( fig.5A, right-panel) . Together, these results suggest that the knockdown of mutp53 and the ensuing reduction of MAP2K3 levels impair p38MAPK signaling. We previously reported that the knockdown of endogenous mutp53 impacts on the proliferation and survival of HT29 and SKBR3 cells (10) . To explore whether MAP2K3 depletion affects mutp53 GOF activities on cell proliferation and cell survival, engineered HT29 cells were plated in the presence (+Dox) or absence (-Dox) of doxycycline and total cell numbers, cell viability, and cell cycle profiles were analyzed in time. MAP2K3 depletion strongly impaired cell proliferation (Fig.5B, left panel) and cell survival (Fig.5B, right panel) and induced significant cell accumulation in G2/M phase (Fig.5C) .
Similar experiments were performed with our other cancer cell lines. We first established that mutp53 enhances proliferation and survival of MDA-MB231 (R280K) and MDA-MB468 (R273H) cell lines. Similarly to HT29 and SKBR3 cells (10) , depletion of mutp53R280K and mutp53R273H, respectively, in MDA-MB231 and MDA-MB468 cells compromises cell proliferation and survival (Suppl. Fig. 2) . Afterward, we explored whether depletion of MAP2K3 compromises proliferation and survival of our other cancer cell lines. Efficient knockdown of MAP2K3 (Suppl. Fig. 3A-C) affects proliferation of all studied cell lines (Fig.  6A-C, left side) and survival of MDA-MB468 and SKBR3 cells (Fig.6A-C, right side) . One possible reason of the different sensitivity to survival of MDA-MB231 may be due to additional survival signals provided by expression of activated mutant Ras protein in these cells (37) . Overall, our findings suggest that, in our panel of cancer cell lines, MAP2K3 upregulation contributes to mutp53 GOF activities. We therefore wished to determine whether MAP2K3 expression might be relevant only for mutp53 expressing cells or might represent a more general required factor. To this aim, we performed RNAi experiments with p53-null H1299 cells. We found that efficient MAP2K3 depletion (Suppl. Fig. 4B ). In conclusion, our data hint MAP2K3 as more general required player in cell proliferation.
Ectopic expression of MAP2K3 can rescue the proliferative defect induced by knockdown of mutp53.
To assess whether MAP2K3 is enable to mediate mutp53 GOF activities, we stably expressed exogenous MAP2K3 in our cohort of human cancer cell lines. Results point out MDA-MB468 cells as more suitable cell-host for stable and sustained expression of ectopic MAP2K3 (Fig. 7A, left panel) . To measure the effect of MAP2K3 on mutp53 GOF activities, stable transfected cells were infected with either the sh/p53 or sh/scr lentivirus and cell proliferation assessed. Depletion of mutp53R273H reduces markedly proliferation of empty vector transfected cells (pcDNA3) (Fig. 7A, right  panel) . In contrast, upon stable ectopic expression of MAP2K3, depletion of mutp53 had little or any effect on cell proliferation of MDA-MB468 cells (Fig. 7A, right panel) . These findings suggest that mutp53 is required for cell proliferation of MDA-MB468 cells and ectopic expression of MAP2K3, as target of mutp53, is sufficient to compensate for mutp53 knockdown.
Finally, to highlight the relevance of our studies, we evaluated the MAP2K3 expression of primary tumors by querying public gene expression data repositories (http://www.oncomine.org/) (38) . Analysis of data sets obtained from specimens of primary tumors revealed that the MAP2K3 transcription is significantly higher in breast (39) and colon (40) cancers carrying p53 mutations in comparison to those carrying wt p53 protein (Fig.7 B) .
In conclusion, our results confirmed MAP2K3 as mutp53 target gene and provide evidence that one of the mechanisms by which mutp53 exerts its GOF activity is through the upregulation of the MAP2K3 expression.
DISCUSSION
Recently reported data indicate that the MAP2K3 upregulation is involved in invasion and progression of glioma and breast tumors. In this study, we show the first evidence that MAP2K3 is transcriptionally upregulated by different endogenous mutp53 proteins in diverse tumor cell lines. Ample data indicate that mutp53 proteins do not only lose their tumor suppressive functions, but they do gain new abilities that promote tumorigenesis by influencing cancer cell transcriptome and phenotype. In particular, we found that knockdown of mutp53 inhibits, whereas ectopic expression of mutp53 increases MAP2K3 transcription. Contrarily, no significant effects were observed upon ectopic expression of wt p53 in p53-null H1299 cells or upon depletion of endogenous wt p53 in HCT116 cell line. These data showed that, in our panel of cancer cell lines, MAP2K3 is likely to be a common target of mutp53 proteins. By analysis for deletions we identified a MAP2K3 regulatory region (-499 to -167) required to mutp53 proteins to modulate MAP2K3 expression. We found that MAP2K3 upregulation occurs by physical recruitment of p53 mutant proteins onto the MAP2K3 regulatory region. Moreover, we found that NF-Y and NF-kB transcriptional co-factors are recruited on MAP2K3 promoter and thus required for MAP2K3 upregulation. Consistently with data in literature, our findings are indicative that both transcriptional co-factors are relevant players in the mutp53 transcriptome. Their involvement in biologic processes such as cell proliferation (NF-Y) and inflammation (NFkB) highlight the relevance of their contribution in mutp53 GOF activity. To better understand the involvement of MAP2K3 upregulation in the mutp53 GOF activity, we explored biologic effects linked to modulation of the MAP2K3 expression in our panel of cancer cell lines. We found that, knockdown of endogenous MAP2K3 inhibits cell proliferation and survival. By contrast, the exogenous expression of MAP2K3 is sufficient to compensate alterations of cell proliferation upon silencing of mutp53.
Moreover by querying public gene expression data repositories we showed a higher expression of MAP2K3 mRNA in specimens of human primary tumors carrying p53 mutations respect to cancers carrying wt p53.
In conclusion, our present study suggests that one possible mechanism through which mutants of p53 may acquire their GOF activities is via upregulation of MAP2K3.
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